Therapeutic effects of a novel BAFF blocker on arthritis

Bailing Zhou¹, Hailong Zhang²,³, Xiaqing Su¹, Yi Luo¹, Xiaopeng Li¹, Chaoheng Yu¹, Qibing Xie¹, Xuyang Xia¹, Gu He¹ and Li Yang¹

INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease, which is not only related to activated T cells and macrophages, but also involved in activated B cells.⁴,⁵ Moreover, B-cell-depleting therapy can improve the symptoms of RA patients.⁶,⁷

B-cell activating factor (BAFF) is a member of the TNF superfamily expressed by macrophages, monocytes, dendritic cells (DCs), stimulated neutrophils, and stromal cells.⁸ Through binding to its receptors, BAFF regulates peripheral B-cell homeostasis and promotes B-cell survival and differentiation.⁹ In the peripheral lymphatic system of BAFF−/− mice, mature B lymphocytes are significantly decreased.⁹ Conversely, overproduction of BAFF in transgenic (TG) mice leads to an enlarged spleen, increased number of mature B cells, and generation of autoimmune diseases resembling RA and systemic lupus erythematosus (SLE).⁹ In addition, BAFF can regulate the function of T cells by enhancing the production of co-stimulatory signals to T cells in conjunction with T cell receptor.¹⁰,¹¹ Thus, BAFF may be an ideal therapeutic target for autoimmune diseases, such as RA.

Several strategies have been used to block BAFF activity, including blocking antibodies,⁴,¹²,¹³ decoy-soluble receptors,¹⁴,¹⁵ and gene silencing.¹⁶ Several BAFF-targeted drugs have been developed for phase II/III clinical research, such as belimumab, tabalumab, and atacicept.¹⁶−¹⁸ Belimumab is the first B-cell-targeted drug that is beneficial in treating SLE, which has been approved by the US Food and Drug Administration (FDA).¹⁹ Latest research data showed belimumab can significantly improve disease activity in SLE patients from North East Asia.¹⁹ Although belimumab can significantly deplete naive B cells, activated B cells, and plasma cells, it has suffered some setbacks in clinical phase III studies of RA, which may relate to patient heterogeneity.¹⁹,²⁰ In addition, previous animal studies have demonstrated that administration of decoy BAFF receptors (TACI-constant region (Fc) and Br3-Fc) effectively inhibits the BAFF-signaling pathway, and then suppresses B-cell maturation and survival, as well as reducing circulating immunoglobulins.¹³,¹⁵ However, both antagonists do not reduce the number of memory B cells that are important for long-term humoral immunity.²¹ Moreover, TACI-Fc can also bind to a proliferation-inducing ligand (APRIL), although the functions of APRIL are poorly understood.²² Recent studies demonstrate that administration of TACI-Fc induces side effects in RA patients and clinical trials of TACI-Fc in RA patients show no difference when compared with control groups, which may be related to the combination between TACI and APRIL and patient heterogeneity.²³,²⁴ Because the binding affinity between Br3 and BAFF is relatively weak, the effectiveness of Br3-Fc has been limited in preclinical and clinical research.¹³ Taken together, these reports underline the need to optimize the efficiency of blocking molecules. Here, we engineer a high-affinity BAFF antagonist (BAFF-Trap) that has improved the deficiencies of TACI-Fc and Br3-Fc. Moreover, BAFF-Trap shows no side effects and effectively inhibits arthritis development and joint destruction in collagen-induced arthritis (CIA) mice and adjuvant-induced arthritis (AIA) rats, which are associated with regulating disease-related immune cells and inhibiting the generation of proinflammatory cytokine.

MATERIALS AND METHODS
Mice
Male 8-week-old DBA/1j mice were purchased from Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China). Male 8-week-old Lewis rats were purchased from Beijing Vital River Laboratories Animal Technology Co. Ltd (Beijing, China). All mice were maintained in a pathogen-free animal facility. All experimental procedures and animal care were performed in accordance with...
the regulations of the Animal Care Committee of Sichuan University.

Cell lines
The Chinese hamster ovary cells (CHO cells) and Burlitt lymphoma and lymphoblastoid cell line (Raji) were obtained from ATCC (Virginia, USA). CHO cells were maintained in F-12 medium (Gibco, California, USA). However, when CHO cells transfected with recombinant plasmids were used to produce targeted protein, the F-12 medium was supplemented with 10% fetal bovine serum (FBS) (Gibco, California, USA). Raji cells were maintained in Rosewell Park Memorial Institute-1640 medium supplemented with 10% FBS.

Expression and purification of BAFF-Trap
First, CHO cells were transfected with the recombinant plasmid, pEF1/V5-BAFF-Trap. Second, cloned strains that stably and efficiently expressed BAFF-Trap were obtained through G418 (2 μg/ml) (Sigma-aldrich, Saint Louis, USA) selection. After intermediate culture of BAFF-Trap-expressing cells, the culture supernatant was collected and loaded onto a protein-A affinity column (GE, Pittsburgh, USA) equilibrated with binding buffer (20 mM phosphate buffer, pH 7.2). The column was washed with 20 mM (pH 7.2) and the hybrid protein was detached with 20 mM PB (pH 7.2) and 100 mM NaCl buffer. The target protein was eluted with 20 mM PB (pH 7.2) and 300 mM NaCl buffer. Eventually, the protein solution was dialyzed with phosphate-buffered saline (PBS).

Western blot analysis
The characterization of BAFF-Trap was confirmed by western blot analysis. First, purified BAFF-Trap was electrophoresed by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride membrane (Bio-Rad, Richmond, USA). After being washed with PBS tween-20 (PBST), the membrane was blocked with 5% skimmed milk powder for 2 h at 37 °C. Then the blots were incubated with goat anti-Br3 antibody or goat anti-TACI antibody (1:1000) (R&D Systems, Minnesota, USA) at 4 °C overnight. The secondary antibody was rabbit anti-goat IgG antibody (horseradish-peroxidase (HR)–conjugated, 1:5000) (ZSGB-BIO, Beijing, China). After each incubation, the membrane was washed five times with PBST (5 min per time). Finally, the protein bands were visualized through a chemiluminescence detection system (Pierce, Rockford, USA).

Enzyme-linked immunosorbent assay (ELISA)
The binding abilities and affinities of BAFF-Trap to BAFF were measured by a specific and sensitive ELISA (R&D Systems, Minnesota, USA), which detects unbound human BAFF at 25 pM (R&D Systems, Minnesota, USA) at 4 °C overnight. The secondary antibody was rabbit anti-goat IgG antibody (horseradish-peroxidase (HR))–conjugated, 1:5000) (ZSGB-BIO, Beijing, China). After each incubation, the membrane was washed five times with PBST (5 min per time). Finally, the protein bands were visualized through a chemiluminescence detection system (Pierce, Rockford, USA).

In vitro pull-down assay
Recombinant protein (200 ng BAFF or APRIL) in 200 μl PBS was incubated with 1 μg of BAFF-Trap, TACI-Fc, or Br3-Fc at 4 °C overnight. Then, 50 μl of protein-A agarose beads was added to the mixture and incubated at 4 °C for 2 h. After centrifugation at 20,000 × g for 3 min, the precipitation containing protein-A conjugated samples was obtained and washed with PBS. The precipitation was eluted with PBS and mixed with SDS-PAGE loading buffer, which was then separated by SDS-PAGE and detected with western blot analysis. The first antibodies were goat anti-human TACI antibody (R&D Systems, Minnesota, USA), rat anti-mouse/human BAFF antibody and mouse anti-human APRIL antibody (R&D Systems, Minnesota, USA), respectively. The corresponding secondary antibodies were HRP-conjugated rabbit (anti-goat, rat and mouse) IgG antibody (ZSGB-BIO, Beijing, China).

Raji cell-binding assay
The expression of TACI and Br3 in Raji cells were validated by flow cytometry. Goat anti-TACI or goat anti-Br3 (10 μg/ml) was added onto Raji cells (1 × 10⁶) and then incubated for 60 min at room temperature. Raji cells were washed with PBS and then incubated with phycoerythrin (PE)-conjugated rabbit anti-goat IgG (BD Biosciences, USA) antibody for 45 min. BAFF-Trap blocking of BAFF binding to Raji cells was also assessed by flow cytometry. In all, 10 μg/ml human BAFF was incubated with various concentrations of BAFF antagonists (5, 10, 20, or 50 μg/ml) for 60 min at 4 °C. The volume was 0.1 ml. Then the mixture was added to Raji cells (2×10⁵) for 30 min at 4 °C. Raji cells were washed with PBS and then incubated with PE-conjugated anti-BAFF antibody (BD Biosciences, New Jersey, USA) for 45 min at 4 °C in the dark. FACSCalibur™ flow cytometer (BD Biosciences, New Jersey, USA) was used in flow cytometry to detect the samples.

BAFF-induced proliferation assay
Raji cell proliferation was measured by CCK-8 cell counting kit (Dojindo, Kumamoto, Japan). A total of 5×10³ Raji cells were plated per well of a 96-well flat bottom plate and incubated for 72 h with vehicle or mixtures of BAFF antagonists (the concentrations ranging from 0.68 nM to11 mM) with 1 μg/ml of BAFF and/or 10 μg/ml of anti-human IgM (R&D Systems, Minnesota, USA), followed by addition of 10 μl of CCK-8 buffer for 2 h. The absorbance of the solution at 450/570 nm was measured by UV spectrophotometer (Shimadzu, Kyoto, Japan).

Generation of CIA model and treatment regimes
To generate the CIA model, bovine CII (Chondrex, WA, USA) was dissolved at 2 mg/ml in 0.05 M acetic acid by stirring overnight at 4 °C and mixed with an equal volume of complete Freund’s adjuvant (Chondrex, WA, USA). After the booster immunization, the severity of CIA was evaluated three times a week for joint edema, erythema, and flexion. Each of the paws was scored from 0 to 4 as previously described. All four paws were scored, and the maximal clinical score per mouse was 16. The body weights of mice were also measured on the same days.

On day 31, most mice showed features of CIA, and were randomly divided into five groups as follows: treated with (i) PBS, (ii) 6 mg/kg BAFF-Trap, (iii) 30 mg/kg BAFF-Trap, (iv) control hIgG (10 mg/kg), or (v) Entanercept (6 mg/kg). All drugs were injected intraperitoneally three times per week, for a total of 18 times. On day 77, paw swelling was measured with a slide gauge, and its degree was assessed by the increase in thickness compared with the thickness of the paws of normal mice.

Generation of AIA model and treatment regimes
Arthritis was induced by Freund’s complete adjuvant (CFA) inoculation of the rats. Rats were infected intradermally at the base of the tail with 0.1 ml CFA (Chondrex, WA, USA).

On day 17, most rats showed features of AIA, and were randomly divided into three groups as follows: treated with (i) PBS, (ii) 4.5 mg/kg hIgG, (iii) 1.5 mg/kg BAFF-Trap. All drugs were injected subcutaneously, once every 2 days, for a total of 15 times.
On day 50, paw swelling was measured with a slide gauge, and its degree was assessed by the increase in thickness compared with the thickness of the paws of normal mice.

Histological assessment
On day 77, mice were killed and joint tissues were harvested. After fixation with 10% formalin/PBS for 24 h, the tissues were decalcified with ethylenediaminetetraacetic acid for 21 days and embedded in paraffin. Then, tissue sections were obtained at 4-μm thickness and stained with hematoxylin-eosin staining (HE). Histological scores of joint pathology were measured by two independent observers as previously described.2,3

Nuclear magnetic resonance imaging (MRI) assessment
Rats were imaged with a Bruker BioSpec 7.0 T MR microimaging system (Bruker, Karlsruhe, Germany) in West China Hospital, Sichuan University (Chengdu, China), using a Bruker rat brain coil array located over both knees. Rats were anesthetized with 1.5–2% isoflurane by nosecone and were physiologically monitored. After the acquisition of a scout view, sagittal, axial, and coronal images of both knees were obtained from each animal with a field of view of 40 mm, a 256 × 256 pixel matrix, and a slice thickness of 1.0 mm using a TurboRARE-T2 sequence with TR 2500 ms.

Measurement of BAFF, anti-CII antibody, and inflammatory-related cytokines levels in serum
The levels of TNF-α, IL-1β, IL-6, and BAFF in serum were measured with ELISA kits (R&D Systems Minnesota, USA) according to the manufacturer’s instructions. In addition, serum levels of anti-CII antibodies were detected using an established ELISA. In brief, the wells of a 96-well plate (Dynatech Laboratories, Chantilly, USA) were coated with 500 ng of purified CII collagen (Sigma-Aldrich, Saint Louis, USA) in 100 μl PBS and incubated at 4 °C overnight. After being washed with PBST three times, the plate was blocked with 5% skimmed milk powder in PBST. The serum samples were obtained at day 42 after treatment and diluted to 1:10,000 and 1:100,000. The diluted serum samples were added to the plate, which was then incubated at 37 °C for 1 h. After washing the plate three times with PBST, total anti-CII antibody levels were detected with HRP-conjugated goat anti-mouse IgG (Southern Biotech, Birmingham, AL), and the IgG subclasses levels were determined using HRP-conjugated goat anti-mouse IgG1, IgG2a, or IgG2b (Southern Biotech, Birmingham, AL). Then, the substrate was developed with 50 μl of 3,3′,5,5′-tetramethylbenzidine (Southern Biotech, Birmingham, AL, USA) for 10 min, and the reaction was stopped with 50 μl of 0.5 M H2SO4. The absorbance was measured at 450 nm and 570 nm with an ELISA reader (Thermo Scientific, Multiskan Mk3, USA).

Reverse transcription and semiquantitative PCR
Total RNA samples from joint tissues were obtained using TRIzol (Invitrogen, California, USA), according to the manufacturer’s instructions. Complementary DNA and PCR were performed with PrimeScript One step RT-PCR kit (Takara, Dalian, China), according to the manufacturer’s instructions. The reactions were validated under the following conditions: first 50 °C for 30 min, then denaturation at 94 °C for 2 min, followed by 98 °C for 10 s, with a final step at 68 °C for 30 s. The amplifications were conducted for 25–30 cycles for the analyzed cytokines. The products were detected by agarose gel electrophoresis using Molecular Imager Gel DOCTM XR + system (Bio-Rad, Richmond, USA), and the band intensity was quantified by Image Lab™ software (Bio-Rad, Richmond, USA). Primer sequences were listed in Supplemental Table I. As an internal control, β-actin primers were used to normalize sample amounts.

Analysis of immune cells from spleen, axillary and peripheral lymph nodes, and joints by flow cytometry
On day 77, mice were killed and spleens, axillary and peripheral lymph nodes, and joints were obtained. Subsets of B lymphocytes from spleen were analyzed by fluorescence activated cell sorting (FACS) (BD Biosciences, New Jersey, USA) after incubation with the following antibody combinations: IgM-FITC/CD19-PE, IgD-FITC/CD19-PE, CD23-FITC/CD19-PE, CD45R-FITC/CD19-PE, and CD27-FITC/CD19-PE. Subsets of T lymphocytes from lymph nodes were stained with the following antibody combinations: CD3-PE/CD4-perCP, CD62L-PE/CD4-perCP, and CD69-PE/CD4-perCP, and then detected by FACS. DCs from joints were analyzed after staining with CD11c-PE/CD11b-FITC antibody combinations, respectively. All antibodies were anti-mouse and purchased from BD Biosciences (New Jersey, USA). Analysis of regulatory T (Treg) cells (CD4+CD25+Foxp3+) from joints was performed using FACS after being stained with the Treg detection kit (Miltenyi Biotec Technology & Trading, Belgish-Gladbach, Germany) according to the manufacturer’s instructions.

Intracellular cytokine staining
Immune cells were obtained from joints as mentioned above. Then, they were incubated with PE-conjugated anti-mouse CD4 antibody for 30 min at 4 °C to stain the cell surface. After being washed with PBS, cells were fixed with 2% paraformaldehyde, permeabilized with 1% Triton-X100, and stained with anti-iFN-γ- FITC or anti-IL-17A-FITC to detect Th1 cells and Th17 cells by FACS. Regulatory B (Breg) cells from joints were also detected with PE-conjugated anti-mouse CD19 and FITC-conjugated IL-10 as mentioned above. The corresponding isotype controls were purchased from BD Biosciences (New Jersey, USA).

Analysis of canonical and noncanonical NF-κB-signaling pathways by western blot
In the presence of hBAFF (100 ng/ml) and anti-hIgM (10 μg/ml), Raji cells expressing BAFF receptors were cultured for 48 h with BAFF-Trap at various concentrations (1.56, 6.25, 25, and 100 μg/ml). Then, cells were homogenized in radioimmunoprecipitation assay lysis buffer and centrifuged for 10 min at 17,000 × g to obtain cell lysate supernatants. The Bradford method was used to determine protein concentrations of the supernatants. The same concentration of protein samples was used to analyze the canonical and noncanonical NF-κB-signaling pathways by western blotting using the above method. The following antibodies purchased from Cell Signaling Technology (Boston, USA) were used as primary antibodies: anti-human phosphorylated Akt, anti-human phosphorylated NIK, anti-human IKKα, anti-human phosphorylated IKKα, anti-human phosphorylated IκBα, anti-human P100, anti-human phosphorylated P100, anti-human P52, anti-human Bcl-2, and anti-human GAPDH. HRP-conjugated rabbit anti-goat IgG antibody (ZSGB-BIO, Beijing, China) was used as a secondary antibody. The signal was visualized using an enhanced chemiluminescence scanner (Pierce, Rockford, USA).

Statistical analysis
SPSS 17.0 was used for statistical analysis. Data were presented as means ± S.D. or medians. Differences between groups were determined by performing analysis of unpaired Student’s t test or one-way ANOVA. The difference was regarded statistically significant if P < 0.05.

RESULTS
Generation and characterization of BAFF-Trap
To design a double decoy receptor, BAFF-Trap, containing sequences of TACI and Br3, the cysteine-rich domain (CRD) 2 of TACI and the CRD of Br3 was fused to the Cc of human IgG1, which
was then cloned into a pEF1/V5 plasmid (Fig. 1a). Moreover, two BAFF-Trap variants were designed, termed B101 and B102, and then purified by Protein-A affinity chromatography and ion exchange chromatography (SP Sepharose), with a purity almost 95% (Fig. 1b). Western blot analysis showed BAFF-Trap could specifically bind to anti-human TACI antibody and anti-human Br3 antibody (Fig. 1c).

In vitro pull-down assays revealed BAFF-Trap could bind to mouse and human BAFF (mBAFF and hBAFF), respectively. Equilibrium binding assays were conducted to determine the binding affinity of BAFF-Trap. The binding affinity of TACI-Fc and Br3-Fc were 1.94 nM and 5.87 nM, respectively, yet B101 had a K_{D} of 3.62 nM, which was higher than for B102 (Fig. 1d). Thus, B101 was termed BAFF-Trap and used for all further experiments.

Equilibrium binding assays were conducted to determine the binding affinity of BAFF-Trap for BAFF. The binding affinity of BAFF-Trap for BAFF was 1.94 nM and 5.87 nM, respectively, yet B101 had a K_{D} of 3.62 nM, which was higher than for B102 (Fig. 1d). Thus, B101 was termed BAFF-Trap and used for all further experiments.

To determine whether BAFF-Trap could efficiently interrupt BAFF binding and activation of its receptors, BAFF-Trap was added to BAFF-cultured Raji cells that expressed TACI and Br3. Although BAFF-Trap contains the CRD2 of TACI, our findings showed that BAFF-Trap could not bind to APRIL (Fig. 1g).
the lowest among the BAFF antagonists tested (Supplemental Fig. 1C). Accordingly, B101 almost completely blocked activated Raji cell proliferation, with an IC_{50} of 50.62 nM (Fig. 1i). Compared with B101, both TACI-Fc and Br3-Fc also potently inhibited BAFF and anti-IgM induced proliferation in Raji cells, with a respective IC_{50} of 69.55 nM and 93.42 nM, which were lower than for B101, yet higher than for B102 (165.4 nM) (Fig. 1i).

BAFF-Trap dramatically inhibits disease development in CIA and AIA model
To explore the value of BAFF-Trap as a BAFF antagonist, we evaluated its ability to inhibit disease development in CIA model. Compared with hlgG and Etanercept treatment, BAFF-Trap significantly inhibited the development of CIA and alleviated the clinical score. However, there were no obvious differences between the 6 and 30 mg/kg of BAFF-Trap treated groups (Fig. 2a, b, Supplemental Fig. 2A). To determine the minimal effective dosage, we examined the ability of 0.67, 2, and 6 mg/kg of BAFF-Trap in CIA. The results showed that 2 mg/kg of BAFF-Trap still effectively inhibited the development of CIA, whereas 0.67 mg/kg of BAFF-Trap did not (Supplemental Fig. 2B–D). Moreover, the ability of B101 was higher than that of B102 (Supplemental Fig. 2B–D). On day 41 after treatment, paw swelling of mice was measured by slide gauge. In comparison with PBS and hlgG treatment, paw thickness was reduced by 50% in the 6 mg/kg BAFF-Trap group and 60% in the 30 mg/kg BAFF-Trap group (Fig. 2c). Importantly, there were differences between the Etanercept and BAFF-Trap treatment groups, paw swelling data showed that BAFF-Trap could significantly reduce 14% paw thickness than Etanercept (Fig. 2c). HE staining assay showed there were no obvious synovial hyperplasia, cartilage damage, lymphocyte infiltration, and bone erosion in BAFF-Trap treated groups, which was almost normal (Fig. 2d, e). These findings indicated that BAFF-Trap effectively inhibited the development of CIA and ameliorated disease severity.

Moreover, the potential toxicity of BAFF-Trap was analyzed. Drug toxicity indices including body weight, renal function, and damage to major organs were closely monitored after mice received indicated treatments. Overall, no marked differences were observed among all groups, and no pathological damages were observed in tissue sections of major organs stained with HE. Moreover, the immunogenicity of BAFF-Trap was measured using serum from mice treated with BAFF-Trap. ELISA detected no antibodies against BAFF-Trap (Fig. 2f).

Besides CIA model, we also evaluated the therapeutic effect of BAFF-Trap in AIA model. Similarly, BAFF-Trap significantly inhibited the development of AIA and alleviated the clinical score compared with PBS and hlgG (Fig. 3a, b), the most effective dosage is 1.5 mg/kg in experimental groups (Supplemental Fig. 3A, B). Synovial hyperplasia, cartilage damage, lymphocyte infiltration, and bone erosion of rat joints in BAFF-Trap treated groups were alleviated consistently, which were examined by HE staining (Fig. 3c, d). To investigate the effect of BAFF-Trap on the repair of rat joints, we examined the ankle joints of rats with MRI at the end of experiment. The results showed that there were obvious bone destruction, cysts and joint effusion in PBS group and hlgG group, whereas BAFF-Trap could repair damaged bone and eliminate joint effusion (Fig. 3e).

BAFF-Trap regulates the development of B cells and the generation of autoantibody by reducing BAFF levels
BAFF levels are elevated in the serum of RA patients and mice with CIA.11,19 To investigate whether BAFF-Trap reduced the amount of BAFF in CIA mice, we measured BAFF levels in the serum of CIA mice at day 42 after treatment. Significantly decreased BAFF serum levels were observed compared with controls, which were similar to normal mouse levels (Fig. 4a). Moreover, we detected the BAFF gene in joints by semiquantitative PCR assay using β-actin as a control. In accordance with the previous results, BAFF gene expression in the PBS treatment group was sixfold higher than that of normal mice, and BAFF-Trap markedly reduced BAFF gene expression (Supplemental Fig. 4A, B). However, compared with PBS treatment, BAFF-Trap did not reduce APRIL gene expression (Supplemental Fig. 4A, B).

BAFF plays an important role in B-cell activation, survival, and development. Overexpression of BAFF in TG mice resulted in the splenic expansion of mature B-1 and B-2 B cells, which are important features in RA patients and CIA mice.27 To determine the effect of BAFF-Trap on B cells, we measured B-cell subtypes in the spleen of mice treated with BAFF-Trap by FACS. There was no significant difference in the weight and volume of spleen of mice among these groups. However, the number of total splenocytes in mice treated with BAFF-Trap was 2.4-fold lower than in control mice, and the number of B cells (CD19^+ CD45R^+ ) was significantly reduced in the spleen (Fig. 4b). In addition, there was a significant decrease in the number of immature transitional B cells (CD19^+ IgM^+ ), from 37.34 ± 3.61% (control mice) to 24.62 ± 2.89% (6 mg/kg BAFF-Trap) and 22.07 ± 1.58% (30 mg/kg BAFF-Trap) (Fig. 4b). This suggests transitional B cells in the spleen depend on BAFF for their development and survival.

In the BAFF-Trap-treated groups, there was a 1.2-fold (6 mg/kg BAFF-Trap) and 1.7-fold (30 mg/kg BAFF-Trap) reduction in splenic naive B cells (CD19^+ IgD^- ), whereas the number of naive B cells was relatively unaffected in Etanercept-treated mice (Fig. 4b). There was also a decrease in CD19^+ activated B-cell expression of CD23, present on the surface of follicular B cells. BAFF-Trap effectively inhibited autoantibody production. The number of plasmablasts and plasma cells (CD19^- CD27^- ) was reduced from 16.15 ± 2.48% in the PBS-treated group to normal levels (5.26 ± 3.63%) in BAFF-Trap-treated groups (Fig. 4b). These findings suggest BAFF is important for the development of these B-cell subtypes, and that BAFF-Trap significantly suppressed the elevated numbers of autoreactive B cells in CIA mice.

Recent studies identified IL-10-secreting B cells that inhibit immune responses and autoimmune diseases such as RA.28 Semiquantitative reverse transcription polymerase chain reaction (RT-PCR) assay showed that IL-10 gene expression was markedly elevated in the joints of BAFF-Trap-treated mice (Supplemental Fig. 4A, B). Joints were digested with collagenase type IV to obtain leukocytes that were stained with fluorescently labeled anti-CD19 and anti-IL-10 antibodies. In the BAFF-Trap-treated group, seven-fold more total numbers of IL-10^+ TACI^- B cells were observed in the joint (Fig. 4c). Interestingly, although BAFF and IL-12 could induce B cells to produce IL-10, their expression was significantly reduced in CIA joints (Supplemental Fig. 4A, B).

The production and enrichment of anti-collagen type II (CII) autoantibodies that contribute to disease development are important features of CIA.23 To determine whether BAFF-Trap inhibited the level of anti-CII autoantibodies, serum was obtained from CIA mice on day 42 after treatment, and used to detect the titer of total IgG and all IgG isoforms against bovine CII. BAFF-Trap markedly decreased the serum level of anti-CII IgG, and mice treated with BAFF-Trap had reduced levels of CII-specific IgG1, IgG2a, and IgG2b antibodies than control mice (Fig. 4d, e). Moreover, IgG2a had the largest proportion among all the IgG isoforms. These findings indicated BAFF-Trap suppressed the development of CIA, in part owing to decreased BAFF levels in mice and the subsequent inhibition of anti-CII antibody production.

BAFF-Trap regulates inflammatory cytokine production
B cells can regulate inflammatory cell production and migration through secreting inflammatory-related cytokines. Proinflammatory cytokines play an important role in CIA pathogenesis.29 To detect changes in proinflammatory cytokines, we performed a
time-course study on the expression of TNF-α, interleukin (IL)-1β, and IL-6 in the serum and found that the concentrations of these cytokines were significantly elevated in PBS and hIgG treated groups, which lasted until the end of the experiment (Fig. 5a–c). However, BAFF-Trap and Etanercept treatment effectively decreased cytokine levels, and there was no difference in levels between these groups until 6 weeks after the first immunization (Fig. 5a–c). Thus, BAFF-Trap significantly suppressed the long-term production of proinflammatory cytokines that mediate CIA.

Similar to protein levels in serum, TNF-α, IL-1β, and IL-6 gene expression was markedly decreased in mice treated with BAFF-Trap compared with control mice (Supplemental Fig. 4A, B). Furthermore, mRNA levels of Th1 cytokines (IL-2, IFN-γ, and IL-12) and Th17 cytokine (IL-17) were markedly reduced in the joints of mice treated with BAFF-Trap. In contrast, the expression of anti-inflammatory cytokines TGF-β and IL-10 were significantly elevated (Supplemental Fig. 4A, B). These findings meant BAFF-Trap could regulate inflammatory cytokine production in joints.
BAFF-Trap suppresses activation of T cells, enhances the roles of regulatory T cells, and attenuates Th1 and Th17 cell functions. TACI and Br3 are expressed by B cells and activated T cells. Moreover, TACI–BAFF interactions are important in the regulation of T-cell activation in the presence of anti-CD3 mAb. Activated T cells are essential for CIA generation and development. To determine whether the effect of BAFF-Trap on CIA disease was related to the inhibition of T-cell activation, lymph nodes were collected from CIA mice and lymphocytes isolated. The number of CD4+ T cells was significantly decreased in mice treated with BAFF-Trap or Etanercept compared with PBS and hIgG treatment groups (Fig. 6a). Analysis of expression markers on CD4+ T cells demonstrated lower expression of activation markers (CD69) and higher expression of unactivated T-cell marker CD62L on CD4+ T cells from mice treated with BAFF-Trap compared with control mice (Fig. 6a). Thus, BAFF-Trap markedly suppressed T-cell activation, which is important in inhibiting CIA development.

Inflammatory cytokines can regulate T-cell polarization, and their production can be influenced by BAFF-Trap. To determine whether T-cell polarization was inhibited by BAFF-Trap, Th1, and Th17 cells in the joints were detected by FACS. In BAFF-Trap-treated mice, significantly reduced numbers of Th1 cells were observed in the joints (Fig. 6b). Semiquantitative RT-PCR assay revealed that mRNA levels of TNF-α, IFN-γ, IL-2, and IL-12 were downregulated. However, the expression of IL-10 was markedly elevated. Th1 differentiation is induced by IFN-γ and IL-12, whereas IL-10 suppresses cytokine production by Th1 cells and Th1 cell-mediated immune responses. IL-10-secreting cell (Treg and Breg cells) numbers in the joints were significantly elevated in BAFF-Trap-treated mice compared with controls (Figs. 4c and 6c). IL-10 produced by regulatory lymphocytes can also suppress the production and differentiation of Th17 cells, which play an important role in the development of CIA disease. To determine the effect of BAFF-Trap on Th17 cells, we measured the number of Th17 cells in joints. As expected, the production of Th17 cells and IL-17 mRNA was significantly suppressed in BAFF-Trap-treated mice (Fig. 6b). Joints of BAFF-Trap-treated mice also showed significantly reduced levels of IL-6, TNF-α, and IL-1β, which contribute to the differentiation of Th17 cells. Interestingly, although an autocrine or paracrine source of TGF-β can
promote generation of Th17 cells, the level of TGF-β in joints was markedly elevated. These data indicate that BAFF-Trap directly and indirectly suppresses the activation and differentiation of T cells.

BAFF-Trap inhibits the generation of DCs in CIA. DCs are antigen-presenting cells that induce naïve T-cell activation and contribute to the expansion of activated T cells. However, the number and function of DCs can be suppressed by regulatory lymphocytes secreting IL-10 or TGF-β. To determine whether DCs were influenced by BAFF-Trap through IL-10 and TGF-β, DCs in the joints were detected by FACS. The numbers of DCs in PBS and hlgG groups were higher than that in normal mice. However, BAFF-Trap markedly suppressed the production of DCs, which was dose-dependent (Fig. 6c, d).

BAFF-Trap suppresses the BAFF-triggered NF-κB pathway. B-cell survival and maturation are mainly mediated by the BAFF/Br3 system, which induces activation of the canonical and noncanonical NF-κB-signaling pathways. Moreover, TACI can...
bind to TNFR-associated factor (TRAF) 2, 5, and 6, contributing to NF-\(\kappa\)B activation. To determine whether BAFF-Trap suppressed NF-\(\kappa\)B activation induced by BAFF/Br3 or BAFF/TACI systems, we treated Raji cells with BAFF, anti-IgM, plus serial concentrations of BAFF-Trap, and examined NF-\(\kappa\)B activation by detecting the phosphorylation of I\(\kappa\)B\(\alpha\) and processing of p100. Consistent with previous reports, Raji cells showed a significantly strong response to the stimulation of BAFF and anti-IgM, as demonstrated by elevated phosphorylation of I\(\kappa\)B\(\alpha\). When treated with BAFF-Trap, Raji cells showed markedly reduced levels of p-I\(\kappa\)B\(\alpha\), which had a distinct dose–response curve (Fig. 7).

Fig. 7 BAFF-Trap reduces the levels of proinflammatory cytokines in CIA mice. a TNF-\(\alpha\), b IL-1\(\beta\), and c IL-6 concentration in serum from CIA mice. The serum was obtained from the first day of immunization, then the levels of proinflammatory cytokines were detected by ELISA. Bars represent mean ± S.D. (\(n = 5\)). **\(P < 0.01\) versus PBS.

DISCUSSION
BAFF has an important role in the generation and development of RA and CIA. When BAFF binds its receptors it induces B-cell maturation, survival and development, but also contributes the activation of T cells, a hallmark of autoimmune diseases.25,30,35 Thus, BAFF is an ideal target for autoimmune diseases associated with RA and CIA.
with lymphocyte hyperactivity, and the neutralization or elimination of BAFF can significantly ameliorate disease severity or suppress the development of autoimmune disorders.36

In this study, we described the development of a novel BAFF antagonist, BAFF-Trap, to treat CIA and AIA. BAFF-Trap binds to different species of BAFF, but not APRIL, whose role is still undefined in RA. Although the affinity of BAFF-Trap for BAFF was slightly lower than TACI-Fc, it was higher than that of Br3-Fc. The bioactivity of therapeutic proteins is key for treating diseases. Our data show that BAFF-Trap had markedly higher bioactivity than TACI-Fc and Br3-Fc for the suppression of Raji cell proliferation, indicating BAFF-Trap might be superior to other BAFF receptor antagonists. Furthermore, BAFF-Trap inhibited lymphocyte activation triggered by NF-κB-signaling pathways, and ameliorated synovial inflammation and joint destruction in CIA and AIA model (Figs. 7 and 8). Based on these findings, BAFF-Trap may be a novel and potential therapeutic protein for the treatment of RA.

In addition to BCR and CD40-mediated signals, B-lymphocyte survival and maturation requires activation of the BAFF/Br3 system pathway.37 After stimulation with BAFF, Br3 preferentially induces the noncanonical NF-κB pathway through binding to TRAF3, contributing to the processing of p100 to p52.33,34 Recent studies showed the noncanonical NF-κB-signaling pathway triggered by Br3 is NIK and IKKα-dependent, and inhibition of Br3 levels suppressed NIK activation and IKKα phosphorylation.38 Our results showed that BAFF significantly elevated the phosphorylation of NIK and IKKα proteins. However, neutralization of BAFF with BAFF-Trap decreased BAFF levels and suppressed activation of the noncanonical NF-κB-signaling pathway. Moreover, the activation of NIK and IKKα proteins was significantly inhibited, and p100 processing to p52 was almost completely blocked. BAFF also promotes B-cell survival through the canonical NF-κB-signaling pathway, which involves the activation of IKK complex and degradation of IkBa.34 Although IKKα is associated with NIK, which takes part in activation of the noncanonical NF-κB pathway as a component of classical IKK complex, its activation also induces the degradation of IkBa that releases p50.

BAFF-triggered NF-κB activation upregulates the expression of antiapoptotic factors, such as Bcl-2, Bcl-xL, and Bfl-1/A1, which contribute to B-cell survival and maturation.33,38 The process of B-cell development is regulated by the balance between B-cell proliferation and apoptosis. In RA patients and CIA mice, B-cell apoptosis is suppressed, contributing to the development of mature B cells and activation of mature B cells. Elevated levels of p52 and Br3 are found in T2 and mature B cells, whereas lower levels are observed in T1 cells.38,39 Moreover, the Btk/c-Rel pathway enhances the expression of Br3 and p100.40 This indicates that BAFF preferentially induces the survival of T2 and mature B cells. This is supported by evidence that loss of BAFF or Br3 results in significant downregulation of T2 and mature B cells, with no obvious changes in T1 B cells. However, significantly reduced numbers of immature transitional B cells (CD19+IgM−) were found in our study. This might be explained by CD19+IgM− B cells being mainly T2 B cells in the spleens of mice treated with BAFF-Trap.

Besides producing immunoglobulins, mature B cells can present antigens to T cells and secrete cytokines.28,31 B cells can function as antigen-presenting cells and deliver co-stimulatory signals (e.g., CD40/CD40L) to T cells, which contributes to T-cell activation.25,31 Moreover, B cells secrete cytokines that regulate the function of T cells, which may occur in autoimmune conditions.31 There are two kinds of B cells: effector B cells and Bregs. Effector B cells secrete IFN-γ and IL-12 that promote Th1 differentiation.28,31 The production of IL-6 and TGF-β by B cells is important for Th17 cell differentiation.11,41 In addition, B cells can also indirectly regulate T-cell function...
through activating DCs. Interestingly, T-cell polarization amplifies the levels of these cytokines, contributing to the production and development of CIA disease.\textsuperscript{11} Nevertheless, Breg cells can suppress T cell responses, but enhance the generation of Tregs, mainly via IL-10 and TGF-β. Breg cells can also inhibit the activation of DCs and macrophages through IL-10.\textsuperscript{28} Recent studies also showed that TACI and BR3 are not only expressed on the surface of B cells but also on the surface of T cells. Soluble BAFF binds to T cells contributing to T cell activation.\textsuperscript{25,30} Thus, our findings show that upregulation of BAFF in mice substantially increases the secretion of proinflammatory cytokines and the proportions of Th1 and Th17 cells, which was ameliorated through administration of BAFF-Trap (Fig. 8).

Although several strategies targeting BAFF have been used to inhibit autoreactive B-cell activation and ameliorate autoimmune disease, the heterogeneity of patient responses and side effects have limited the development and application of these strategies. Although belimumab was therapeutic in a clinical phase II/III study in RA patients and was approved by the FDA to treat SLE patients, patient heterogeneity has limited its clinical phase III study.\textsuperscript{13} Meanwhile, Atacicept (TACI-Fc) can cause infections, related to the rapid decline of serum IgG.\textsuperscript{13,42} In this study, we did not observe obvious immunopathology in mice treated with BAFF-Trap. The levels of Breg and Treg cells were significantly elevated, although some studies have described that approaches targeting B cells can also reduce Breg cells. However, the level of BAFF was elevated in all CIA mice, which was normalized after treatment with BAFF-Trap. However, not all patients are responsive to BAFF-dependent B-cell-directed therapy, and the role of BAFF-Trap in CIA mice should be further studied.\textsuperscript{13,42}

In conclusion, this study demonstrated that BAFF-Trap effectively reduces the levels of autoimmune IgG and activated lymphocytes, and suppressed the development of CIA and AIA without serious side effects. Thus, BAFF-Trap may be a novel and effective strategy to treat autoimmune disorders.

ACKNOWLEDGEMENTS
This study was supported by the National Major Scientific and Technological Special Project for "Significant New Drugs Development" (No. 2012ZX09103301-025, No. 2012ZX09201018-013, and No. 2012ZX09733001), China Postdoctoral Science Foundation (No. 2018M633370).

AUTHOR CONTRIBUTIONS
L.Y. contributed to study design. B.Z., H.Z., Y.W., X.S., Y.L., X.L., and C.Y. contributed to data and figures collection. Q.X., X.X., and G.H. contributed to literature search.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41392-019-0051-z) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Vital, E. M. & Emery, P. The development of targeted therapies in rheumatoid arthritis. J. Autoimmun. 31, 219–227 (2008).
2. La, D. T., Collins, C. E., Yang, H. T., Migone, T. S. & Stohl, W. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders. Ann. Rheum. Dis. 67, 1132–1138 (2008).
3. Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581 (2004).
4. Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).
5. Moore, P. A. et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260–263 (1999).
6. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995–999 (2000).
7. Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108–2111 (2001).
8. Mackay, F., Sierro, F., Grey, S. T. & Gordon, T. P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243–265 (2005).
9. Hsu, B. L., Harless, S. M., Lindsay, R. C., Hillbert, D. M. & Cancro, M. P. Cutting edge: BlyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168, 5993–5996 (2002).
10. Huard, B., Schneider, P., Mauri, D., Tischopp, J. & French, L. E. T cell costimulation through the TNF ligand BAFF. J. Immunol. 167, 6225–6231 (2001).
11. Lai Kwan Lam, Q., King Hung Ko, O., Zheng, B. J. & Lu, L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. USA 105, 14993–14998 (2008).
12. Furie, R. et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BlyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Rheum. Ther. 2, R109 (2008).
13. Stohl, W. Biologic differences between various inhibitors of the BlyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr. Rheumatol. Rep. 14, 303–309 (2012).
14. Carbonatto, M. et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol. Sci. 105, 200–210 (2008).
15. Vugmeyster, Y. et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168, 476–489 (2006).
16. Zhang, F. et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann. Rheum. Dis. 77, 355–363 (2018).
17. Genovese, M. C. et al. Tabulumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naïve to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 65, 880–889 (2013).
18. van Vollenhoven, R. F., Kimman, N., Vincent, E., Wax, S. & Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782–1792 (2011).
19. Furie, R. et al. A phase III, randomised, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
20. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
21. Levesque, M. C. & St Clair, E. W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121, 13–21 (2008).
22. Mackay, F., Silveira, P. A. & Brink, R. B cells and the BAFF/APRIL axis: fast-forward understanding of B cell biology and implications for therapy. Nat. Rev. Immunol. 6, 626–632 (2006).
23. Dall’Era, M. et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Ann. Intern. Med. 143, 101–109 (2005).
24. Brennan, F. M. & McInnes, I. B. Evidence that cytokines play a role in rheumatoid arthritis. Nat. Rev. Immunol. 6, 626–632 (2006).
25. Bossen, C. & Schneider, P. BAFF and APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18, 263–275 (2006).
26. Kim, H. M. et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat. Struct. Mol. Biol. 15, 342–348 (2008).
27. Yang, M., Rui, K., Wang, S. & Lu, L. Regulatory B cells in autoimmune diseases. Cell. Mol. Immunol. 10, 122–132 (2013).
28. Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell development. Nat. Rev. Immunol. 6, 626–632 (2006).
29. Brennan, F. M. & McInnes, I. B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118, 3537–3545 (2008).
30. Mackay, F. & Leung, H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 18, 284–289 (2006).
31. Hamze, M., Desmetz, C. & Guglielmi, P. B cell-derived cytokines in disease. Eur. Cytokine Netw. 24, 20–26 (2013).
32. Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305–317 (2006).
33. Claudio, E., Brown, K., Park, S., Wang, H. & Siebenlist, U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3, 958–965 (2002).
34. Morrison, M. D., Reiley, W., Zhang, M. & Sun, S. C. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the non-canonical NF-kappaB signaling pathway. J. Biol. Chem. 280, 10018–10024 (2005).
35. Batten, M. et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192, 1453–1466 (2000).
36. Steinman, L., Merrill, J. T., McInnes, I. B. & Peakman, M. Optimization of current and future therapy for autoimmune diseases. Nat. Med. 18, 59–65 (2012).
37. Xu, L. G. & Shu, H. B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappaB activation and IL-10 production. J. Immunol. 169, 6883–6889 (2002).
38. Pham, L. V. et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways. Blood 117, 200–210 (2011).
39. Woodland, R. T. et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111, 750–760 (2008).
40. Castro, I. et al. B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2. J. Immunol. 182, 7723–7737 (2009).
41. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
42. Hahn, B. H. Belimumab for systemic lupus erythematosus. N. Engl. J. Med. 368, 1528–1535 (2013).